Caribou Biosciences (CRBU) EBIAT (2020 - 2025)
Caribou Biosciences (CRBU) has disclosed EBIAT for 6 consecutive years, with -$26.5 million as the latest value for Q4 2025.
- On a quarterly basis, EBIAT rose 25.36% to -$26.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$148.1 million, a 0.66% increase, with the full-year FY2025 number at -$148.1 million, up 0.66% from a year prior.
- EBIAT was -$26.5 million for Q4 2025 at Caribou Biosciences, up from -$27.5 million in the prior quarter.
- In the past five years, EBIAT ranged from a high of -$10.0 million in Q3 2023 to a low of -$54.1 million in Q2 2025.
- A 5-year average of -$28.3 million and a median of -$27.3 million in 2022 define the central range for EBIAT.
- Peak YoY movement for EBIAT: plummeted 664.48% in 2021, then surged 62.47% in 2023.
- Caribou Biosciences' EBIAT stood at -$18.5 million in 2021, then crashed by 46.05% to -$27.0 million in 2022, then dropped by 27.72% to -$34.5 million in 2023, then decreased by 2.96% to -$35.5 million in 2024, then increased by 25.36% to -$26.5 million in 2025.
- Per Business Quant, the three most recent readings for CRBU's EBIAT are -$26.5 million (Q4 2025), -$27.5 million (Q3 2025), and -$54.1 million (Q2 2025).